Search

Your search keyword '"Spinal Fractures prevention & control"' showing total 1,007 results

Search Constraints

Start Over You searched for: Descriptor "Spinal Fractures prevention & control" Remove constraint Descriptor: "Spinal Fractures prevention & control"
1,007 results on '"Spinal Fractures prevention & control"'

Search Results

1. Undiagnosed vertebral fragility fractures in patients with distal radius fragility fractures: an opportunity for prevention of morbimortality in osteoporotic patients in developing countries.

2. The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project.

3. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?

4. Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures.

5. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies.

6. The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis.

7. A Real-world Study of Denosumab For Reducing Refracture Risk after Percutaneous Vertebral Augmentation.

8. Prevention and Management of Denosumab Discontinuation Rebound Fractures.

9. Risk factors for vertebral fracture in rheumatoid arthritis patients using biological disease-modifying anti-rheumatic drugs (cases over 5 years): An observational study.

10. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.

11. Letters to the Editor for "Association between dental diseases and oral hygiene care and the risk of vertebral fracture: a nationwide cohort study".

12. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).

13. The positive impact of smoking cessation on fracture risk in a nationwide cohort study.

14. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

15. The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.

16. An online clinical decision tool to screen for vertebral fragility fractures (Vfrac) in older women presenting with back pain in general practice: protocol for a feasibility study in preparation for a future cluster randomised controlled trial.

17. Efficacy and Safety of Anti-Osteoporotic Agents across CKD Stages: A Meta-Analysis of Randomized Clinical Trials.

18. Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly.

19. Effects of hospitalist co-management on rate of initiation of osteoporosis treatment in patients with vertebral compression fractures: Retrospective cohort study.

20. Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults.

21. [Brittle bones].

22. [Development of the new guidelines on osteoporosis : Methodological and content development].

23. Establishment of a novel risk prediction model for recompression of augmented vertebrae at the thoracolumbar junction and modified puncture technique for prevention: a multicenter retrospective study.

24. Effect of hormone replacement therapy on intervertebral disc height.

25. Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis.

26. Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study.

27. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

28. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.

29. Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.

30. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.

31. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.

32. [Denosumab and fracture risk in kidney transplant].

33. The efficacy of prophylactic vertebroplasty for preventing proximal junctional complications after spinal fusion: a systematic review.

34. Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.

35. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.

36. Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency.

37. Examining the protective role of the posterior elements of the spine against endplate fractures in a porcine model.

38. [A randomized double-blinded placebo-controlled clinical trial of minodronate tablet in postmenopausal Chinese women with osteoporosis].

39. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

40. Finite Element Analysis of a New Type of Spinal Protection Device for the Prevention and Treatment of Osteoporotic Vertebral Compression Fractures.

41. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.

42. The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS).

43. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.

44. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.

45. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.

46. Does prophylactic vertebral augmentation reduce the refracture rate in osteoporotic vertebral fracture patients: a meta-analysis.

47. Assessment of non-traumatic vertebral fractures in Cushing's syndrome patients.

48. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.

49. Efficacy of annual zoledronic acid in initial percutaneous kyphoplasty patients with osteoporotic vertebral compression fractures: a 3-year follow-up study.

50. An easy way to determine bone mineral density and predict pelvic insufficiency fractures in patients treated with radiotherapy for cervical cancer.

Catalog

Books, media, physical & digital resources